The obesity drug semaglutide (Wegovy) carried a significantly higher risk of ischemic optic neuropathy (ION) than other GLP-1 agonists. An analysis of FDA data showed this risk to be higher compared to semaglutide for diabetes (Ozempic). ION can lead to blindness. Wegovy is approved for the treatment of obesity, Ozempic for type 2 diabetes. Both drugs contain the same active substance semaglutide, but differ in dosage and indications. The study highlights the different risks between the two drugs.